PL2419097T3 - Kompozycja farmaceutyczna zawierająca (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitol i metforminę oraz jej zastosowanie w leczeniu cukrzycy - Google Patents

Kompozycja farmaceutyczna zawierająca (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitol i metforminę oraz jej zastosowanie w leczeniu cukrzycy

Info

Publication number
PL2419097T3
PL2419097T3 PL10764570T PL10764570T PL2419097T3 PL 2419097 T3 PL2419097 T3 PL 2419097T3 PL 10764570 T PL10764570 T PL 10764570T PL 10764570 T PL10764570 T PL 10764570T PL 2419097 T3 PL2419097 T3 PL 2419097T3
Authority
PL
Poland
Prior art keywords
ethoxybenzyl
glucitol
anhydro
metformin
thio
Prior art date
Application number
PL10764570T
Other languages
English (en)
Inventor
Teisuke Takahashi
Saeko Uchida
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of PL2419097T3 publication Critical patent/PL2419097T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10764570T 2009-04-16 2010-04-16 Kompozycja farmaceutyczna zawierająca (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitol i metforminę oraz jej zastosowanie w leczeniu cukrzycy PL2419097T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
EP10764570.7A EP2419097B1 (en) 2009-04-16 2010-04-16 Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
PCT/JP2010/057196 WO2010119990A1 (en) 2009-04-16 2010-04-16 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PL2419097T3 true PL2419097T3 (pl) 2014-02-28

Family

ID=42982643

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10764570T PL2419097T3 (pl) 2009-04-16 2010-04-16 Kompozycja farmaceutyczna zawierająca (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitol i metforminę oraz jej zastosowanie w leczeniu cukrzycy
PL13157571T PL2601949T3 (pl) 2009-04-16 2010-04-16 Kompozycje farmaceutyczne z (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitolem oraz substancją zwiększającą wydzielanie insuliny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13157571T PL2601949T3 (pl) 2009-04-16 2010-04-16 Kompozycje farmaceutyczne z (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitolem oraz substancją zwiększającą wydzielanie insuliny

Country Status (30)

Country Link
US (1) US20120040898A1 (pl)
EP (3) EP2601949B1 (pl)
JP (4) JP5077786B2 (pl)
KR (2) KR20150046382A (pl)
CN (7) CN102395364A (pl)
AR (1) AR076317A1 (pl)
AU (1) AU2010237748B2 (pl)
BR (1) BRPI1012539A2 (pl)
CA (1) CA2755392A1 (pl)
CY (2) CY1114703T1 (pl)
DK (2) DK2419097T3 (pl)
ES (2) ES2431300T3 (pl)
HK (6) HK1217302A1 (pl)
HR (2) HRP20131120T1 (pl)
ME (2) ME01555B (pl)
MX (1) MX2011010901A (pl)
MY (3) MY156679A (pl)
NZ (4) NZ710575A (pl)
PH (3) PH12015500235A1 (pl)
PL (2) PL2419097T3 (pl)
PT (2) PT2601949E (pl)
RS (2) RS53056B (pl)
RU (2) RU2532330C2 (pl)
SG (6) SG2014012553A (pl)
SI (2) SI2419097T1 (pl)
SM (1) SMT201500015B (pl)
TW (3) TW201622720A (pl)
UA (2) UA111742C2 (pl)
WO (1) WO2010119990A1 (pl)
ZA (1) ZA201106727B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
IN2012DN02751A (pl) 2009-09-30 2015-09-18 Boehringer Ingelheim Int
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6234443B2 (ja) 2012-05-17 2017-11-22 ブイティーブイ・セラピューティクス・エルエルシー 糖尿病治療のためのグルコキナーゼ活性化因子組成物
CN104780942A (zh) * 2012-08-30 2015-07-15 大正制药株式会社 Sglt2抑制剂和抗高血压药的组合
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR102309654B1 (ko) 2013-04-18 2021-10-08 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
SG11201707008SA (en) * 2015-02-27 2017-09-28 Asan Found Composition for preventing or treating valve calcification, containing dpp-4 inhibitor
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
US20210212968A1 (en) 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
US11439689B2 (en) * 2016-11-14 2022-09-13 Kaohsiung Medical University Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
AU2002254567B2 (en) * 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
CA2655937A1 (en) * 2006-06-29 2008-01-03 Taisho Pharmaceutical Co., Ltd. C-phenyl 1-thioglucitol compound
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 1−チオ−d−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
EP2054426A1 (en) * 2006-08-15 2009-05-06 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
WO2008055940A2 (en) * 2006-11-09 2008-05-15 Boehringer Ingelheim International Gmbh Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
EP2103607A4 (en) * 2006-12-14 2011-01-05 Taisho Pharmaceutical Co Ltd 1-phenyl-1-thio-D-GLUCITOLDERIVAT
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo

Also Published As

Publication number Publication date
SG2014014807A (en) 2014-05-29
EP2419097B1 (en) 2013-09-25
EP2601949B1 (en) 2014-10-29
SG2014012405A (en) 2014-05-29
EP2829271A3 (en) 2015-05-27
US20120040898A1 (en) 2012-02-16
HK1218871A1 (zh) 2017-03-17
JP5660094B2 (ja) 2015-01-28
NZ710575A (en) 2016-06-24
HK1217301A1 (zh) 2017-01-06
HRP20131120T1 (hr) 2013-12-20
NZ606888A (en) 2014-07-25
PL2601949T3 (pl) 2015-04-30
MY182720A (en) 2021-02-03
CN105477639A (zh) 2016-04-13
UA105216C2 (en) 2014-04-25
ZA201106727B (en) 2012-11-28
EP2601949A2 (en) 2013-06-12
JP5077786B2 (ja) 2012-11-21
NZ595314A (en) 2013-03-28
JP6066144B2 (ja) 2017-01-25
JP2015063543A (ja) 2015-04-09
PH12019500959B1 (en) 2020-06-29
NZ623838A (en) 2015-09-25
EP2419097A1 (en) 2012-02-22
TW201500043A (zh) 2015-01-01
PH12019500961A1 (en) 2020-08-03
RU2011146335A (ru) 2013-05-27
EP2829271A2 (en) 2015-01-28
HRP20141080T1 (hr) 2015-01-02
MY183793A (en) 2021-03-16
ME01555B (me) 2014-04-20
BRPI1012539A2 (pt) 2016-03-29
SG2014012553A (en) 2014-05-29
RU2532330C2 (ru) 2014-11-10
MY156679A (en) 2016-03-15
PH12019500959A1 (en) 2020-06-29
SG175154A1 (en) 2011-11-28
DK2419097T3 (da) 2013-10-28
SMT201500015B (it) 2015-03-05
EP2601949A3 (en) 2013-09-18
ES2523408T3 (es) 2014-11-25
JP2013006854A (ja) 2013-01-10
SG2014015093A (en) 2014-04-28
CY1115907T1 (el) 2017-01-25
CN105343880A (zh) 2016-02-24
PT2601949E (pt) 2014-11-12
CY1114703T1 (el) 2016-10-05
HK1217302A1 (zh) 2017-01-06
JP2016104775A (ja) 2016-06-09
ES2431300T3 (es) 2013-11-25
CN105343059A (zh) 2016-02-24
AU2010237748B2 (en) 2014-10-30
TW201622720A (zh) 2016-07-01
RS53056B (en) 2014-04-30
PH12015500235B1 (en) 2015-12-02
CN105343871A (zh) 2016-02-24
DK2601949T3 (da) 2015-01-05
WO2010119990A1 (en) 2010-10-21
EP2419097A4 (en) 2012-09-05
AU2010237748A1 (en) 2011-10-20
UA111742C2 (uk) 2016-06-10
PH12015500235A1 (en) 2015-12-02
SG2014012462A (en) 2014-05-29
CN105434430A (zh) 2016-03-30
PH12019500961B1 (en) 2020-08-03
RS53761B1 (en) 2015-06-30
AR076317A1 (es) 2011-06-01
TW201103534A (en) 2011-02-01
JP5910711B2 (ja) 2016-04-27
PT2419097E (pt) 2013-10-03
ME02015B (me) 2015-05-20
CN102395364A (zh) 2012-03-28
MX2011010901A (es) 2011-11-01
CN105343060A (zh) 2016-02-24
HK1218881A1 (zh) 2017-03-17
JP2012524710A (ja) 2012-10-18
KR20150046382A (ko) 2015-04-29
HK1217434A1 (zh) 2017-01-13
HK1217435A1 (zh) 2017-01-13
SI2601949T1 (sl) 2014-12-31
KR20120016051A (ko) 2012-02-22
SI2419097T1 (sl) 2014-01-31
CA2755392A1 (en) 2010-10-21
RU2014121260A (ru) 2015-12-10

Similar Documents

Publication Publication Date Title
PL2419097T3 (pl) Kompozycja farmaceutyczna zawierająca (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitol i metforminę oraz jej zastosowanie w leczeniu cukrzycy
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
HRP20180653T1 (hr) FARMACEUTSKI PRIPRAVAK KOJI SADRŽI desPro36Exendin-4(1-39)-Lys6-NH2 I METIONIN
IL250548A0 (en) Acetyl analogs of insulin that are resistant to protease and their use for the preparation of a drug for the treatment and prevention of diabetes
IL215925A0 (en) Electrokinetically-altered fluid compositions and use thereof for treating insulin resistance and diabetes mellitus
IL219309A (en) History of glycoside, including pharmaceutical preparations and their use in the preparation of diabetes medications
EP2120959A4 (en) METHOD AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES AND DIABETES-BASED DYSLIPIDEMIA
IL199397A (en) Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products
IL219945A (en) 1-GLP history with dual transduction and use of it to prepare a drug for the treatment of diabetes
IL198289A (en) Processed dihydropyrazolones, processes for their preparation, medicinal preparations containing them and their use in the preparation of medicinal preparations
IL216006A (en) Processed aromatic compounds, pharmaceutical preparations including them and their use in the manufacture of pharmaceuticals
IL218644A0 (en) Pharmaceutical composition having the active substances metformin and sitaglipin or vildagliptin
PT2315773T (pt) Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente
IL215592A (en) Compounds, preparations containing them and their uses in the treatment or prevention of conditions in the eyes
IL208463A (en) 2-Trotocyclic-Pirol compounds combined, pharmaceutical preparations containing them and their use in the prevention or treatment of diabetes or obesity
EP2519240A4 (en) PHARMACEUTICAL COMPOSITION WITH METFORMIN AND ROSUVASTATIN
HK1167348A1 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
PT2557920E (pt) Composição que compreende uma membrana de casca de ovo em pó para utilização no tratamento de diabetes mellitus
PT2459207E (pt) Composição farmacêutica para tratamento de condições médicas e um método para tratamento de distúrbios alimentares e doenças relacionadas
SI2266619T1 (sl) Farmacevtski sestavek na osnovi hepatoprotektorja in prebiotika, njegova izdelava in uporaba
IL211267A (en) Oxadiazole derivatives and drugs and their use in the treatment of diabetes
HK1171010A1 (en) 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity 4-(124--3-)
AP2011005766A0 (en) Use of racemates of pinocembrin in preparing medicaments for treating stroke.
IL218069A (en) Oligoscride compounds, drug, pharmaceutical, and compound for its use in therapy
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative